exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087789 RNA Name: hsa-miR-148b-3p RNA Type: miRNA Chromosome: chr12 Starnd: + Coordinate: Start Site(bp): 54337278 End Site(bp): 54337299 External Links: hsa-miR-148b-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand E2F1 chr20 33675477 33686385 - EMP1 chr12 13196723 13219941 + FAM47E-STBD1 chr4 76251721 76311129 + KLF4 chr9 107484852 107490482 - LENG8 chr19 54448887 54462037 + LYSMD4 chr15 99715697 99733561 - MLPH chr2 237485428 237555322 + MTMR9 chr8 11284816 11328146 + NDST1 chr5 150485818 150558211 + OSBPL11 chr3 125528858 125595497 - PBXIP1 chr1 154944076 154956123 - PFAS chr17 8247618 8270491 + PGRMC1 chrX 119236245 119244466 + RCC1 chr1 28505943 28539300 + RTKN chr2 74425835 74442422 - STARD13 chr13 33103137 33350630 - STBD1 chr4 76306026 76311599 + SYVN1 chr11 65121780 65134533 - TBC1D5 chr3 17157162 18444817 - TMEM123 chr11 102396332 102470384 - TOMM70 chr3 100363431 100401089 - TRIM3 chr11 6448613 6474459 - USP22 chr17 20999596 21043760 - VPS45 chr1 150067279 150145329 + ZNF512B chr20 63956704 63969930 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001454 chr4 154524454 154533552 + hsa_circ_0000384 chr12 27867712 27877119 + hsa_circ_0000284 chr11 33307958 33309057 + hsa_circ_0000943 chr19 47421744 47440665 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC007780.1 chr17 68413623 68524949 + AC073896.4 chr12 56162359 56190284 - AL049840.4 chr14 103694516 103695050 - AL603839.3 chr1 40493157 40508661 - H19 chr11 1995176 2001470 - HCG18 chr6 30286690 30327382 - KCNQ1OT1 chr11 2608328 2699994 - LINC01089 chr12 121795267 121803906 - NEAT1 chr11 65422774 65445540 + NUTM2A-AS1 chr10 87201647 87342612 - NUTM2B-AS1 chr10 79661394 79826594 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.